review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Michael P. Busch | Q6833284 |
David A Leiby | Q90319989 | ||
Celso Bianco | Q114430369 | ||
Susan L Stramer | Q66751416 | ||
P2093 | author name string | Lily Lin | |
Mark E Brecher | |||
Morris A Blajchman | |||
Jean Pierre Allain | |||
P2860 | cites work | Chronic wasting disease and potential transmission to humans | Q24599755 |
Transfusion-associated babesiosis after heart transplant | Q24610281 | ||
Detection of Babesia microti by polymerase chain reaction | Q24658352 | ||
Eliminating Trachoma in Areas with Limited Disease | Q29037878 | ||
Avian influenza and human health. | Q30330442 | ||
Nucleic acid testing for emerging viral infections | Q30721623 | ||
Identification and characterization of putative secreted antigens from Babesia microti | Q30885688 | ||
First results using automated epifluorescence microscopy to detect Escherichia coli and Staphylococcus epidermidis in WBC-reduced platelet concentrates | Q32040603 | ||
Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study | Q33338131 | ||
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial | Q33345486 | ||
Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura | Q33348253 | ||
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada | Q73460291 | ||
Detection of bacteria in WBC-reduced PLT concentrates using percent oxygen as a marker for bacteria growth | Q73811096 | ||
Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections | Q74418641 | ||
HBV: amplified and back in the blood safety spotlight | Q74500188 | ||
Fatal Clostridium perfringens sepsis from a pooled platelet transfusion | Q74503592 | ||
Dengue fever on the increase | Q74539620 | ||
Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients | Q77451463 | ||
Parvovirus B19 DNA in plasma pools and plasma derivatives | Q77793402 | ||
Inactivation of HIV in blood | Q78493198 | ||
From the Centers for Disease Control and Prevention. Investigations of West Nile virus infections in recipients of blood transfusions | Q78611566 | ||
Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats | Q95719295 | ||
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial | Q33360736 | ||
Approaches to the detection of bacterial contamination in cellular blood products | Q33602575 | ||
Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports | Q33623655 | ||
Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States | Q33875842 | ||
The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions | Q33900392 | ||
Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor | Q33978508 | ||
The use of riboflavin for the inactivation of pathogens in blood products | Q34000406 | ||
Human babesiosis: an emerging tick-borne disease | Q34102705 | ||
Incidence and significance of the bacterial contamination of blood components. | Q34148581 | ||
Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light | Q34322353 | ||
Medically important arboviruses of the United States and Canada | Q34336519 | ||
Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient | Q34339769 | ||
Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective | Q34451441 | ||
Bacterial contamination of platelet concentrates: incidence, significance, and prevention | Q34451446 | ||
Inactivation of cytomegalovirus in platelet concentrates using Helinx technology | Q34451451 | ||
Virus inactivation in blood components by photoactive phenothiazine dyes | Q34491789 | ||
Bacterial contamination of blood products: factors, options, and insights | Q34522392 | ||
Viral meningitis and encephalitis: traditional and emerging viral agents | Q34535781 | ||
Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer | Q34996364 | ||
Transfusion medicine: looking to the future | Q35047211 | ||
Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage. | Q35052861 | ||
Safety of the blood supply: role of pathogen reduction | Q35087058 | ||
Airport malaria: report of a case and a brief review of the literature. | Q35103177 | ||
Risks associated with transfusion of cellular blood components in canada | Q35122220 | ||
Pathogen reduction technology: methods, status of clinical trials, and future prospects | Q35560787 | ||
Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection. | Q35607877 | ||
Improving the bacteriological safety of platelet transfusions | Q35613174 | ||
Viral hepatitis: from A to E, and beyond? | Q35613967 | ||
Improving platelet safety: bacterial contamination of platelets | Q35668474 | ||
Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion | Q38473724 | ||
Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. | Q39740523 | ||
Local transmission of Plasmodium vivax malaria--Palm Beach County, Florida, 2003 | Q40549714 | ||
Transmission of West Nile Virus through Blood Transfusion in the United States in 2002 | Q40550030 | ||
West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation | Q40554292 | ||
Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. | Q40571207 | ||
Identification of Babesia microti-specific immunodominant epitopes and development of a peptide EIA for detection of antibodies in serum | Q40622880 | ||
Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry | Q40689418 | ||
Transfusion-associated Chagas' disease in Texas: report of a case | Q40750204 | ||
Rocky mountain spotted fever caused by blood transfusion | Q40875178 | ||
Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria | Q41461282 | ||
Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. | Q41468943 | ||
The use of a chemiluminescence‐linked universal bacterial ribosomal RNA gene probe and blood gas analysis for the rapid detection of bacterial contamination in white cell‐reduced and nonreduced platelets | Q41503213 | ||
Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors | Q42665299 | ||
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma | Q42980958 | ||
Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light | Q42982277 | ||
Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. | Q42996768 | ||
Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies | Q43037065 | ||
Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population | Q43040535 | ||
SEN virus infection and its relationship to transfusion-associated hepatitis | Q43601229 | ||
Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function | Q43655377 | ||
Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States | Q43727179 | ||
Duck hepatitis B photoinactivation bydimethylmethylene blue in RBC suspensions | Q43734115 | ||
Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors | Q43740289 | ||
Use of riboflavin for photoinactivation of pathogens in blood components | Q43887055 | ||
Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study | Q43918917 | ||
Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period | Q44170176 | ||
Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin | Q44210527 | ||
First report of human immunodeficiency virus transmission via an RNA-screened blood donation | Q44326279 | ||
Transmission of parasites by blood transfusion | Q44368419 | ||
A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets | Q44579149 | ||
Transfusion-associated acute Chagas disease acquired in the United States | Q45031981 | ||
Virus photoinactivation in stroma-free hemoglobin with methylene blue or 1,9-dimethylmethylene blue | Q45744856 | ||
Virus Inactivated Single-Donor Fresh Plasma Preparations | Q45865281 | ||
Current and emerging infectious risks of blood transfusions | Q46883397 | ||
Inactivation of mycoplasma species in blood by INACTINE PEN110 process. | Q47206402 | ||
Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies | Q47608681 | ||
Single-donor platelets reduce the risk of septic platelet transfusion reactions | Q49166133 | ||
Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB. | Q50509806 | ||
Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. | Q50517766 | ||
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. | Q51037857 | ||
Electrochemiluminescent detection of bacteria in blood components. | Q52545960 | ||
Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivation. | Q52842012 | ||
Inactivation of parvovirus B19 during pasteurization of human serum albumin. | Q53955493 | ||
Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS) | Q55239955 | ||
From the Centers for Disease Control and Prevention. Local transmission of Plasmodium vivax malaria--Virginia 2002 | Q56447274 | ||
Transfusion-associated Trypanosoma cruzi infection in a non-endemic area | Q58845305 | ||
Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion | Q58847043 | ||
Evaluation of a reporting system for bacterial contamination of blood components in the United States | Q64128634 | ||
Parvovirus B19 infection | Q71103605 | ||
[First documentation of transfusion-associated babesiosis in Japan] | Q73046346 | ||
Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity | Q73205703 | ||
Rapid identification of bacterially contaminated platelets using reagent strips: glucose and pH analysis as markers of bacterial metabolism | Q73277637 | ||
Evaluation of donor skin disinfection methods | Q73277667 | ||
Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations | Q73402681 | ||
P433 | issue | 2 | |
P921 | main subject | emerging pathogen | Q108429945 |
P304 | page(s) | 110-126 | |
P577 | publication date | 2005-04-01 | |
P1433 | published in | Transfusion Medicine Reviews | Q15758511 |
P1476 | title | Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. | |
P478 | volume | 19 |
Q47556754 | Amustaline (S-303) treatment inactivates high levels of Chikungunya virus in red-blood-cell components. |
Q28729789 | Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components |
Q93541706 | Bacterial contamination of platelet concentrates: pathogen detection and inactivation methods |
Q37715077 | Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality |
Q37589285 | Consensus and controversies in platelet transfusion |
Q38332335 | Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands |
Q41452764 | Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation |
Q91955390 | Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study |
Q50201431 | Healing of a soft tissue wound of the neck and jaw osteoradionecrosis using platelet gel. |
Q26741073 | Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use |
Q50563846 | Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. |
Q33852543 | Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. |
Q42236941 | Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. |
Q50705094 | Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. |
Q22330681 | Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination |
Q38158233 | Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination |
Q39284167 | Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination |
Q38667338 | Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria |
Q33396311 | Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction |
Q33397396 | Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system |
Q34006006 | Microcalorimetry: a novel method for detection of microbial contamination in platelet products |
Q35095646 | Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ |
Q41935541 | Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione |
Q43807105 | Pathogen inactivation of platelets: organization consequences for platelet transfusion |
Q37013124 | Pathogen inactivation: making decisions about new technologies. Report of a consensus conference |
Q28544736 | Pathogen reduction in human plasma using an ultrashort pulsed laser |
Q50655717 | Pathogen reduction: a precautionary principle paradigm. |
Q26739936 | Platelet gel: a new therapeutic tool with great potential |
Q46356432 | Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment |
Q92597042 | Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione |
Q39263574 | Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system |
Q38220202 | Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion |
Q28733459 | Prevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation |
Q37595112 | Problem of bacterial contamination in platelet concentrates |
Q83795700 | Protecting the blood supply from emerging pathogens: the role of pathogen inactivation |
Q38084362 | Proteomics applied to transfusion plasma: the beginning of the story |
Q50217763 | Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies |
Q37062415 | Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma |
Q47572436 | Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment |
Q91471131 | Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes |
Q33394967 | Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients |
Q45357266 | Simultaneous triple point-of-care testing for HIV, syphilis and hepatitis B virus to prevent mother-to-child transmission in India. |
Q24614152 | The influence of riboflavin photochemistry on plasma coagulation factors |
Q37798900 | The status of pathogen-reduced plasma |
Q27480405 | Transfusion-transmitted infections |
Q39847980 | Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series |
Q33370956 | Treatment of thrombotic thrombocytopenic purpura. |
Q33394914 | Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion |
Q37809341 | Umbilical Cord Blood Transplantation for Thalassemia Major |
Q37166900 | Updates on pathogen inactivation of plasma using Theraflex methylene blue system |
Q33788326 | Use of hemovigilance data to evaluate the effectiveness of diversion and bacterial detection |
Q37671773 | Why implement universal leukoreduction? |
Q24261255 | Zika Virus |
Search more.